Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update
Competitor Analysis: CD19-Targeted Therapeutics – 2016 Update
This Competitive Intelligence report about CD19-Targeted Therapeutics provides a competitor evaluation in the field of antibody- and T-cell-based therapeutics for the treatment of B-cell hematologic malignancies as of April 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of antibodies and T-cells targeting CD19. In addition, the report lists company-specific R&D pipelines of CD19-Targeted Therapeutics. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
This Competitive Intelligence report about CD19-Targeted Therapeutics provides a competitor evaluation in the field of antibody- and T-cell-based therapeutics for the treatment of B-cell hematologic malignancies as of April 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of antibodies and T-cells targeting CD19. In addition, the report lists company-specific R&D pipelines of CD19-Targeted Therapeutics. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Competitor Analysis: CD19-Targeted Therapeutics – 2016 Update
1. CD19-Targeted Therapeutics:
1. CD19-Targeted Therapeutics:
- Fc-Engineered CD19-Targeted Antibodies
- CD19-Targeted Antibody-Drug Conjugates
- CD19-Targeted Immunotoxin
- Bispecific, CD19-Targeted and T-Cell Recruiting Monoclonal Antibodies
- Other CD19-Targeted Bispecific Monoclonal Antibodes
- Autologous CD19-Targeted Chimeric Antigen Receptor T-Cells
- Allogeneic CD19-Targeted Chimeric Antigen Receptor T-Cells
